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ABSTRACT 
We report the discovery of three co-crystals of acetylsalicylic acid (ASA). The co-crystals include 
different co-crystal formers (CCFs) containing pyridine moieties: 4,4’-bipyridine (4,4’-bipy), 4,4'-
butane-1,4-diyldipyridine (4,4’-butane), and trans-bis(4-pyridyl)poly-2-ene (4-pyr-poly-2-ene). 
The three co-crystals are 2(ASA)·(4,4’-bipy), 2(ASA)·(4,4’-butane), and 2(ASA)·(4-pyr-poly-
2-ene). All the co-crystals were formed by rapid solvent evaporation of diethyl ether. 
2(ASA)·(4,4’-bipy) was also formed using dry grinding. The three co-crystals consist of three-
component hydrogen-bonded assemblies held together by O-H···N hydrogen bonds. Both 
2(ASA)·(4,4’-bipy) and 2(ASA)·(4,4’-butane) form catemers between ASA molecules, while 
2(ASA)·(4-pyr-poly-2-ene) forms dimers between ASA molecules. These X-ray structures show 
similarity to how ASA interacts with itself when it is crystallized in its single-component form. 
Understanding and characterizing how ASA self-assembles with other molecules may benefit the 
pharmaceutical industry and help to influence bulk properties of aspirin.3-6  
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INTRODUCTION 
Supramolecular chemistry is the study of molecular recognition processes, or chemistry 
that is beyond the individual molecule. Supramolecular chemistry studies non-covalent 
interactions focusing on interactions such as hydrogen-bonding and van der Waals forces. The 
goal of this research is to study how molecules in the form of co-crystals self-assemble in the solid 
state. Molecules within solids will self-assemble as to maximize the number of non-covalent 
interactions with neighboring molecules.1 Co-crystallization is the process of self-assembly 
between two or more molecules. We use co-crystallizations to study how different types of 
molecules self-assemble and interact to form new solid forms. We obtain X-ray diffraction data 
that can be used to help determine reliable and directional interactions between two molecules. 
The process of co-crystallization is now being applied in pharmaceuticals to affect the properties 
of solids containing active pharmaceutical ingredients (APIs).2  
Co-crystallizing an API with other molecules enables us to modulate the bulk properties of 
solid formulations. Some of the bulk properties that can be modulated during a co-crystallization 
include solubility, bioavailability, and stiffness.3,4,5,6  Co-crystallization can also impact tableting 
and milling processes used in the pharmaceutical industry.7 Furthermore, forming and 
characterizing new co-crystals can expand intellectual property and new patents.3  In co-
crystallizations, the API is combined with an additional molecule capable of participating in non-
covalent interactions, known as co-crystal formers (CCFs). For this research, aspirin (ASA) was 
used as an API, and co-crystal formers that were able to participate in hydrogen-bonding with 
aspirin were selected.  
 To point out the significance of this research, it is important to note a co-crystal that can 
be effective for modulating properties of solids. The first FDA-approved pharmaceutical co-
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crystal, known as Entresto, consists of two APIs known as sacubitril and valsartan.8 Entresto 
allows people with a low left ventricular ejection fraction and heart failure to have well-managed 
symptoms and to take two medications in one pill.7 For many consumers, this may be useful 
because taking multiple pills can be tedious and often easy to forget which pills have already been 
taken. A co-crystal like Entresto enables patients to get specialized care, as well.7 Entresto serves 
as a model for what possibilities await pharmaceutical co-crystals.  
Aspirin, in contrast to Entresto, is a molecule that has been understood for quite some time. 
It is often used as a model compound in pharmaceutical research and in drug delivery kinetics.9 
Aspirin in a non-steroidal anti-inflammatory drug that helps to alleviate fevers, pain, and helps to 
prevent blood clots, heart attacks, and strokes when taken regularly.10,11 It is a well-known and 
studied molecule, which makes it appealing to use to characterize how it interacts with other 
molecules. Aspirin serves as a model for characterizing hydrogen bonds and crystal packing. If 
interactions of aspirin with co-crystal formers can be fully understood, new co-crystals can be 
made and characterized.12 Also, aspirin is commonly combined with other medications.13 
Therefore, we wanted to utilize aspirin as our model compound of interest to study how aspirin 
specifically interacts with other molecules and to follow and be able to predict any packing 
preferences it may possess. Moreover, not many co-crystals containing aspirin have been reported 
in the literature. A possible reason for the lack of co-crystals of aspirin may be due to the fact that 
aspirin is readily hydrolyzed to salicylic acid, making it difficult to isolate and characterize the co-
crystals.14,15,16,17,18,19,20,21,22 
The new co-crystals described here can be important for the development of 
pharmaceutical co-crystals containing aspirin. Here we report the isolation and characterization of 
three co-crystals of aspirin, or acetylsalicylic acid (ASA) and three pyridine-based CCFs: 4,4’-
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bipyridine (4,4’-bipy), 4,4'-butane-1,4-diyldipyridine (4,4’-butane), and trans-bis(4-pyridyl)poly-
2-ene (4-pyr-poly-2-ene). Specifically, we use acid-pyridine O-H···N hydrogen bonding to afford 
2(ASA)·(4,4’-bipy), 2(ASA)·(4,4’-butane), and 2(ASA)·(4-pyr-poly-2-ene) (Scheme 1). We 
demonstrate that aspirin molecules prefer to form methyl C-H···O catemers or dimers, similar to 
those seen in the single-component forms of aspirin. 
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Scheme 1. Generation of three novel ASA co-crystals. 
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EXPERIMENTAL 
Grinding experiment: Crystalline powders of ASA (50.1 mg, 0.29 mmol) and 4,4’-bipy 
(21.7 mg, 0.14 mmol) were mixed with a spatula. The components were then ground together with 
a mortar-and-pestle. The combined and ground solids were each characterized using PXRD in 
approximate 5 min. increments.  
Co-crystal syntheses: The solvent used for all the co-crystallization experiments, diethyl 
ether, was purchased from Fisher Scientific. ASA was purchased from Sigma-Aldrich while 4,4’-
bipy and 4,4’-butane were purchased from Acros. All chemicals were used as received. The diene 
CCF, 4-pyr-poly-2-ene was synthesized according to literature.23 For the synthesis of 
2(ASA)·(4,4’-bipy), ASA (54.2 mg, 0.30 mmol) and 4,4’-bipy (23.4 mg, 0.15 mmol) were 
dissolved in separate vials in a minimal amount of diethyl ether. Each vial was heated to a boil and 
then the contents in each vial combined. The solution was allowed to cool to room temperature 
slowly. After ca.24 h, colorless crystals of 2(ASA)·(4,4’-bipy) formed which were suitable for 
single-crystal X-ray diffraction (SCXRD). For the synthesis of  2(ASA)·(4,4’-butane), ASA (18.2 
mg, 0.10 mmol) and 4,4’-butane (10.8 mg, 0.051 mmol) were added in separate vials and 
dissolved in a minimum amount of diethyl ether while bringing the solutions to a boil. 
Combination of the two solutions and slow evaporation over a period of ca. 48 h yielded colorless 
crystals suitable for SCXRD. For the formation of 2(ASA)·(4-pyr-poly-2-ene), ASA (51.7 mg, 
0.29 mmol) and 4-pyr-poly-2-ene (59.9 mg, 0.29 mmol) were added to separate vials as described 
above for the other two co-crystallization experiments. After ca.48 h, colorless crystals were 
obtained that were analyzed by SCXRD.  
Single-crystal X-ray diffraction (SCXRD): SCXRD data were measured on a Bruker 
Neditonius APEX II Kappa diffractometer for (ASA)·(4,4’-bipy) and on a  Nonius KappaCCD 
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diffractometer for 2(ASA)·(4,4’-butane) and 2(ASA)·(4-pyr-poly-2-ene) using Mo Kα radiation 
(λ = 0.71073 Å) and a graphite monochromator equipped with an Oxford Cryostream low 
temperature device. Crystals were mounted in Paratone oil on a Mitegen magnetic mount. Lorentz 
and polarization corrections were applied and programs from the APEXII package were used for 
data reduction. Solution and refinement were accomplished by direct methods using ShelXL24 and 
ShelXT25 in Olex226 graphical user interface. All non-hydrogen atoms were refined using 
anisotropic displacement parameters. 
Powder X-ray diffraction (PXRD): PXRD data were collected on a Bruker D-8 
ADVANCE X-ray diffractometer using Cu Kα radiation (λ = 1.54056 Å) and a LynxEye detector. 
Samples were collected from 5° to 45° 2θ (count time: 1 sec. per step, step size: 0.02°). Millimeter-
sized crystals were ground into powders with an agate mortar-and-pestle and mounted on a glass 
slide. 
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RESULTS AND DISCUSSION 
Co-crystallization by dry mechanochemistry of 2(ASA)·(4,4’-bipy): An original report 
of a co-crystal with ASA and 4,4’-bipy used a two solvent system of hexane and diethyl ether. 
The result was 2(ASA)·(4,4’-bipy)·x(hexane), which included channels filled with hexane.27 
Since the goal of our research was to form co-crystals with ASA and 4,4’-bipy without solvent 
inclusion, we attempted grinding the two components together without solvent (i.e., dry grinding). 
The transformation that took place started with  the physical mixture of single components and 
resulted in the 2(ASA)·(4,4’-bipy) co-crystal (Figure 1). The PXRD diffractograms show data 
collected taken at different time periods in the process of dry grinding the two neat components of 
ASA and 4,4’-bipy. The appearance of new peaks at 16.8°, 17.2°, and 25.0° in 2θ indicates the 
formation of the new crystalline phase without the use of solvents. When comparing PXRD data 
from the single components (bottom) with the product of dry grinding after 20 min (top), it can be 
concluded that a new solid was formed and was not simply a physical mixture of the two single 
components (Figure 2).   
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Figure 1. PXRD of the mixture between ASA and 4,4’-bipy (bottom) and neat dry grinding 
recorded at intervals as the co-crystal formed.  
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Figure 2. PXRD from grinding the two neat components (top) compared to the two single 
components (bottom). 
Co-crystals of 2(ASA)·(4,4’-bipy): Single crystals of 2(ASA)·(4,4’-bipy) were obtained 
by dissolving ASA (2 mol. equiv.) and 4,4’-bipy (1 mol. equiv.) separately in minimal boiling 
diethyl ether. Millimolar concentrations were used to obtain colorless, blade-like crystals suitable 
for SCXRD. Single crystals of 2(ASA)·(4,4’-bipy) were characterized by SCXRD. We note that 
the PXRD simulated diffractogram matches the PXRD data obtained after 20 min of dry grinding.  
The components of 2(ASA)·(4,4’-bipy) crystallize in the triclinic space group P1̅ (Figure 
3, Table 1). The components form a three-component assembly of 2(ASA)·(4,4’-bipy) held 
together by two OH···N hydrogen bonds (Figure 3). The acyl functional groups from ASA adopt 
an anti-conformation within the three-component assembly. The two-dimensional packing of 
11 
 
2(ASA)·(4,4’-bipy) exhibits parallel columnar packing (Figure 4). The three-dimensional packing 
of 2(ASA)·(4,4’-bipy) shows a herringbone arrangement of columns (Figure 5). 
 
 
Figure 3. X-ray structure of 2(ASA)·(4,4’-bipy) (a) assembly 1 and (b) assembly 2 (ORTEP view 
at 50 % probability).  
 
Figure 4. Extended packing of hydrogen-bonded assemblies of 2(ASA)·(4,4’-bipy) showing 
columnar packing. 
 
(a) 
(b) 
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Table 1. Crystal data and structure refinement for 2(ASA)·(4,4’-bipy). 
Empirical formula  C28H24N2O8  
Formula weight  516.49  
Temperature/K  298.15  
Crystal system  triclinic  
Space group  P-1  
a/Å  7.578(3)  
b/Å  16.015(5)  
c/Å  23.130(8)  
α/°  70.044(5)  
β/°  88.535(5)  
γ/°  81.694(5)  
Volume/Å3  2610.0(16)  
Z  4  
ρcalcg/cm3  1.314  
μ/mm-1  0.097  
Crystal size/mm3  0.24 × 0.12 × 0.05  
Radiation  MoKα (λ = 0.71073)  
Reflections collected  43726  
Independent reflections  9138 [Rint = 0.0570, Rsigma = 0.0481]  
Data/restraints/parameters  9138/0/695  
Goodness-of-fit on F2  1.079  
Final R indexes [I>=2σ (I)]  R1 = 0.0721, wR2 = 0.1895  
Final R indexes [all data]  R1 = 0.1229, wR2 = 0.2186  
 
Figure 5. Herringbone stacking view of 2(ASA)·(4,4’-bipy). 
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 The hydrogen-bonded three-component assemblies of ASA and 4,4’-bipy are also held 
together by catemeric methyl C-H···O forces between ASA molecules (Figure 6). The ASA 
molecules form a staggered conformation when hydrogen-bonded to one another (Figure 6). 
 
Figure 6. C-H···O catemers formed between ASA molecules of 2(ASA)·(4,4’-bipy). 
Co-crystals of 2(ASA)·(4,4’-butane): Single crystals of 2(ASA)·(4,4’-butane) were 
obtained by dissolving separately ASA (2 mol. equiv.) and 4,4’-butane (1 mol. equiv.) in minimal 
boiling diethyl ether. Millimolar concentrations were needed to obtain colorless, prism-like 
crystals suitable for SCXRD. Solid 2(ASA)·(4,4’-butane) was characterized by SCXRD. 
 
 
Figure 7. X-ray structure of 2(ASA)·(4,4’-butane) (ORTEP view at 50 % probability). 
 The components of 2(ASA)·(4,4’-butane) crystallize in the monoclinic space group P21/n 
(Figure 7, Table 2). The components form a three-component assembly of 2(ASA)·(4,4’-butane) 
held together by two OH···N hydrogen bonds (Figure 7). The acyl functional groups from ASA 
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adopt an anti-conformation within the three-component assembly (Figure 7). The extended 
packing of 2(ASA)·(4,4’-butane) forms parallel columns of three-component assemblies in two 
different orientations (Figure 8). In three-dimensions, 2(ASA)·(4,4’-butane) packs in off-set 
columns to form parallel stacks (Figure 9).  
Table 2. Crystal data and structure refinement for 2(ASA)·(4,4’-butane) 
Empirical formula  C32H32N2O8  
Formula weight  572.59  
Temperature/K  298.15  
Crystal system  monoclinic  
Space group  P21/n  
a/Å  12.4020(12)  
b/Å  7.6704(8)  
c/Å  16.5223(17)  
α/°  90  
β/°  110.780(5)  
γ/°  90  
Volume/Å3  1469.5(3)  
Z  2  
ρcalcg/cm3  1.294  
μ/mm-1  0.094  
Crystal size/mm3  0.19 × 0.18 × 0.14  
Radiation  MoKα (λ = 0.71073)  
Reflections collected  8693  
Independent reflections  2577 [Rint = 0.0248, Rsigma = 0.0255]  
Data/restraints/parameters  2577/0/192  
Goodness-of-fit on F2  1.030  
Final R indexes [I>=2σ (I)]  R1 = 0.0411, wR2 = 0.1064  
Final R indexes [all data]  R1 = 0.0633, wR2 = 0.1192  
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Figure 8. Extended two-dimensional packing of hydrogen-bonded assemblies of 2(ASA)·(4,4’-
butane).  
 
 
Figure 9. Extended three-dimensional packing of hydrogen-bonded assemblies of 2(ASA)·(4,4’-
butane), which exhibits parallel stacks.  
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ASA molecules in 2(ASA)·(4,4’-butane) also form C-H···O catemers between methyl 
groups and the acetoxy groups (Figure 10). This catemeric structure consists of alternating ASA 
molecules, forming a zig-zag pattern of hydrogen-bonding (Figure 10). The catemers help to 
stabilize the three-component assembly of 2(ASA)·(4,4’-butane) and connect the segregated 
stacks.  
 
Figure 10. C-H···O catemers formed between ASA molecules in 2(ASA)·(4,4’-butane).  
Co-crystals of 2(ASA)·(4-pyr-poly-2-ene): Single crystals of 2(ASA)·(4-pyr-poly-2-
ene) were obtained by dissolving separately ASA (2 mol. equiv.) and 4-pyr-poly-2-ene (1 mol. 
equiv.) in minimal boiling diethyl ether. Millimolar concentrations were needed to obtain 
colorless, plate-like crystals suitable for SCXRD. Solid 2(ASA)·(4-pyr-poly-2-ene) was 
characterized by SCXRD.  
 
Figure 11. X-ray structure of 2(ASA)·(4-pyr-poly-2-ene) (ORTEP view at 50 % probability).  
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Table 3. Crystal data and structure refinement for 2(ASA)·(4-pyr-poly-2-ene). 
Empirical formula  C32H28N2O8  
Formula weight  568.56  
Temperature/K  298.15  
Crystal system  triclinic  
Space group  P-1  
a/Å  7.5302(8)  
b/Å  8.7062(8)  
c/Å  11.3528(11)  
α/°  88.879(5)  
β/°  75.301(5)  
γ/°  83.479(5)  
Volume/Å3  715.23(12)  
Z  1  
ρcalcg/cm3  1.320  
μ/mm-1  0.096  
Crystal size/mm3  0.31 × 0.23 × 0.1  
Radiation  MoKα (λ = 0.71073)  
Reflections collected  5095  
Independent reflections  2912 [Rint = 0.0171, Rsigma = 0.0312]  
Data/restraints/parameters  2912/0/192  
Goodness-of-fit on F2  1.038  
Final R indexes [I>=2σ (I)]  R1 = 0.0476, wR2 = 0.1226  
Final R indexes [all data]  R1 = 0.0790, wR2 = 0.1418  
 
The components of 2(ASA)·(4-pyr-poly-2-ene) crystallize in the triclinic space group P1̅ 
(Figure 11, Table 3). The components form a three-component assembly of 2(ASA)·(4-pyr-poly-
2-ene) held together by two OH···N hydrogen bonds (Figure 11). The acyl functional groups from 
ASA adopt an anti-conformation within the three-component assembly (Figure 11). In two-
dimensions, 2(ASA)·(4-pyr-poly-2-ene) forms parallel columns (Figure 12). 2(ASA)·(4-pyr-
poly-2-ene) forms segregated stacks when its three-dimensional structure is observed (Figure 13). 
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Figure 12. Extended packing of hydrogen-bonded assemblies of 2(ASA)·(4-pyr-poly-2-ene) in 
parallel columns.  
 
Figure 13. Extended packing of hydrogen-bonded assemblies of 2(ASA)·(4-pyr-poly-2-ene) in 
three dimensions, showing segregated stacks.  
The three-component assembly of 2(ASA)·(4-pyr-poly-2-ene) forms dimers between 
ASA molecules that help to stabilize the structure. The C-H···O dimers form between methyl 
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groups and acetoxy groups of each ASA molecule (Figure 14). The orientation of the ASA 
molecules is that so that hydrogen-bonding is maximized, and these hydrogen bonds form a 
rectangle, connecting each ASA molecule in two places (Figure 14). 
 
Figure 14. C-H···O dimers formed between ASA molecules in 2(ASA)·(4-pyr-poly-2-ene). The 
dimers are circled in red.  
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CONCLUSIONS 
Here we have shown the successful creation and analysis of three novel ASA co-crystals. 
All the co-crystals were created using slow evaporation of diethyl ether. 2(ASA)·(4,4’-bipy) was 
created using mechanochemistry alone, as well. The three-component assemblies of the three 
novel co-crystals all had anti-conformations of the acetyl groups on ASA. Furthermore, the co-
crystals all formed either catemers or dimers between ASA molecules, which is very similar to the 
synthons that ASA forms when it is crystallized in its single-component form. This information 
helps us to better understand the interactions that form between ASA and other co-crystal formers 
and helps to better predict what kind of packing will occur when ASA is left to self-assemble with 
other molecules.  
21 
 
REFERENCES  
1.  Schneider, H.-J. Binding mechanisms in supramolecular complexes Angew. Chem. Int. Ed. 
Engl. 2009, 48, 3924 – 3977. 
2.  Duggirala, N. K.; Perry, M. L.; Almarsson, O.; Zaworotko, M. J.  Pharmaceutical cocrystals: 
along the path to improved medicines. Chem. Commun. 2016, 52, (4), 640-655. 
3.  Bolla, G.; Nangia, A.  Pharmaceutical cocrystals: walking the talk. Chem. Commun. 2016, 52, 
(54), 8342-8360. 
4.  Aitipamula, S.; Banerjee, R.; Bansal, A. K.; Biradha, K.; Cheney, M. L.; Choudhury, A. R.; 
Desiraju, G. R.; Dikundwar, A. G.; Dubey, R.; Duggirala, N.; Ghogale, P. P.; Ghosh, S.; 
Goswami, P. K.; Goud, N. R.; Jetti, R. R. K. R.; Karpinski, P.; Kaushik, P.; Kumar, D.; 
Kumar, V.; Moulton, B.; Mukherjee, A.; Mukherjee, G.; Myerson, A. S.; Puri, V.; Ramanan, 
A.; Rajamannar, T.; Reddy, C. M.; Rodriguez-Hornedo, N.; Rogers, R. D.; Row, T. N. G.; 
Sanphui, P.; Shan, N.; Shete, G.; Singh, A.; Sun, C. C.; Swift, J. A.; Thaimattam, R.; Thakur, 
T. S.; Kumar Thaper, R.; Thomas, S. P.; Tothadi, S.; Vangala, V. R.; Variankaval, N.; 
Vishweshwar, P.; Weyna, D. R.; Zaworotko, M. J.  Polymorphs, Salts, and Cocrystals: 
What’s in a Name? Cryst. Growth Des. 2012, 12, (5), 2147-2152. 
5.  Bučar, D.-K.; Lancaster, R. W.; Bernstein, J.  Disappearing Polymorphs Revisited. Angew. 
Chem. Int. Ed. 2015, 54, (24), 6972-6993. 
6.  Sander, J. R. G.; Bučar, D.-K; Henry, R. F.; Baltrusaitis, J.; Zhang, G. G. Z.; MacGillivray, L. 
R. A Red Zwitterionic Co-Crystal of Acetaminophen and 2,4-Pyridinedicarboxylic Acid. J. 
Pharm. Sci. 2010, 99 (9), 3676-3683.  
7.  Tan, D.; Loots, L.; Friscic, T. Towards Medicinal Mechanochemistry: Evolution of Milling 
from Pharmaceutical Solid Form Screening to the Synthesis of Active Pharmaceutical 
Ingredients (APIs). Chem. Commun. 2016, 52 (50), 7760-7781. 
8.  Melchiorri, D. Assessment report: Entresto. European Medicines Agency. 2015, 1-115.  
9.  Shanthala, H. K.; Hirethota, Shreyas; Jain, Kirti; Chandra, Naveen. Development and 
characterization of aspirin - sucrose complex for improved drug delivery. J. Pharma Bio Sci. 
2016, 7 (3), 54-60. 
10. Jin J. Nonsteroidal Anti-inflammatory Drugs. JAMA. 2015;314(10):1084. 
11. Ittaman SV, VanWormer JJ, Rezkalla SH. The Role of Aspirin in the Prevention of 
Cardiovascular Disease. Clinical Medicine & Research. 2014, 12 (3-4),147-154. 
12. Oburn, S. M.; Ray, O.A.; MacGillivray, L. R. Elusive Nonsolvated Cocrystals of Aspirin: 
Two Polymorphs with Bipyridine Discovered with the Assistance of Mechanochemistry.       
Cryst. Growth Des. 2018, 18, 2495-2501.  
13. Archibugi, L.; Piciucchi, M.; Stigliano, S.; Valente, R.; Zerboni, G.; Barucca, V.; Milella, 
M.; Maisonneuve, P.; Delle Fave, G.; Capurso, G. Exclusive and Combined Use of Statins 
and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study. Sci. Rep. 2017, 7. 
14. Vishweshwar, P.; McMahon, J. A.; Oliveira, M.; Peterson, M. L.; Zaworotko, M. J.  The 
Predictably Elusive Form II of Aspirin. J. Am. Chem. Soc. 2005, 127, (48), 16802-16803. 
15. Bond, A. D.; Boese, R.; Desiraju, G. R.  On the Polymorphism of Aspirin. Angew. Chem. Int. 
Ed. 2007, 46, (4), 615-617. 
16. Kendrick, J.; Montis, R.; Hursthouse, M. B.; Leusen, F. J. J.  “In-Silico Seeding”: 
Isostructurality and Pseudoisostructurality in a Family of Aspirin Derivatives. Cryst. Growth 
Des. 2013, 13, (7), 2906-2915. 
                                                          
22 
 
                                                                                                                                                                                           
17. Sarma, B.; Nath, N. K.; Bhogala, B. R.; Nangia, A.  Synthon Competition and Cooperation in 
Molecular Salts of Hydroxybenzoic Acids and Aminopyridines. Cryst Growth Des. 2009, 9, 
(3), 1546-1557. 
18. Cheney, M. L.; Weyna, D. R.; Shan, N.; Hanna, M.; Wojtas, L.; Zaworotko, M. J.  Coformer 
Selection in Pharmaceutical Cocrystal Development: a Case Study of a Meloxicam Aspirin 
Cocrystal That Exhibits Enhanced Solubility and Pharmacokinetics. J. Pharm. Sci. 100, (6), 
2172-2181. 
19. Zegarac, M.; Leksic, E.; Sket, P.; Plavec, J.; Devcic Bogdanovic, M.; Bucar, D.-K.; Dumic, 
M.; Mestrovic, E.  A sildenafil cocrystal based on acetylsalicylic acid exhibits an enhanced 
intrinsic dissolution rate. CrystEngComm 2014, 16, (1), 32-35. 
20. Stepanovs, D.; Jure, M. r.; Kuleshova, L. N.; Hofmann, D. W. M.; Mishnev, A.  Cocrystals 
of Pentoxifylline: In Silico and Experimental Screening. Cryst Growth Des. 2015, 15, (8), 
3652-3660. 
21. Caira, M. R.  Molecular complexes of sulfonamides. 2.1:1 complexes between drug 
molecules: sulfadimidine-acetylsalicylic acid and sulfadimidine-4-aminosalicylic acid. J. 
Crystallogr. Spectrosc. Res. 1992, 22, (2), 193-200. 
22. Thakur, T. S.; Desiraju, G. R.  Crystal Structure Prediction of a Co-Crystal Using a 
Supramolecular Synthon Approach: 2-Methylbenzoic Acid−2-Amino-4-methylpyrimidine. 
Cryst. Growth Des. 2008, 8, (11), 4031-4044. 
23. Carsky,P.; Hünig, S.; Stemmler, I.; Scheutzow, D.; Liebigs. Ann. Chem. 1980, 291– 304. 
24. Sheldrick, G.  Crystal structure refinement with SHELXL. Acta Crystallogr. Sect.C 2015, 71, 
(1), 3-8. 
25. Sheldrick, G.  SHELXT - Integrated space-group and crystal-structure determination. Acta 
Crystallogr. Sect. A 2015, 71, (1), 3-8. 
26. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.  OLEX2: a  
complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42,     
(2), 339-341. 
27. Walsh, R. D. B.; Bradner, M. W.; Fleischman, S.; Morales, L. A.; Moulton, B.; Rodriguez-
Hornedo, N.; Zaworotko, M. J.  Crystal engineering of the composition of pharmaceutical 
phases. Chem. Commun. 2003, (2), 186-187. 
